Teva Highlights New UZEDY Data in Schizophrenia Care
Parsippany, New Jersey, September 21, 2026 Teva Pharmaceuticals has announced new real-world data for UZEDY® (risperidone) extended-release injectable suspension,...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology immunology Immunotherapy Medical Device Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
Parsippany, New Jersey, September 21, 2026 Teva Pharmaceuticals has announced new real-world data for UZEDY® (risperidone) extended-release injectable suspension,...
Shanghai and Hong Kong, PRC, September 21, 2026 Antengene Corporation Limited has announced the dosing of the first patient...
Tel Aviv, Israel, September18, 2026 Teva Pharmaceutical Industries Ltd. has announced new post hoc clinical data for TEV-‘749, its...
